Cat. No.: HY-13585

Copy Link Print Information

Carmustine

(Synonyms: BCNU)

11 Cited Publications

Avis client

Based on 11 publication(s) in Google Scholar

Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.91%
CAS No.: 154-93-8
Formule: C₅H₉Cl₂N₃O₂
Masse moléculaire:214.05

Stockage:

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Carmustine Chemical Structure

CAS No.: 154-93-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (11)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Carmustine is an antitumor chemotherapeutic agent, which works by akylating DNA and RNA.

IC₅₀ & Target

DNA Alkylator^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A 172	IC₅₀	18 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay	[PMID: 2391696]
A-427	IC₅₀	8 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay	[PMID: 2391696]
A498	IC₅₀	110 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay	[PMID: 2391696]
A549	IC₅₀	90 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay	[PMID: 2391696]
Astrocyte	IC₅₀	155.6 μM Compound: BCNU	Cytotoxicity against rat astrocytes Cytotoxicity against rat astrocytes	[PMID: 16970409]
Astrocyte	EC₅₀	54.8 μM Compound: 1, BCNU, Carmustine	Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method Cytotoxicity against Rattus norvegicus Sprague-Dawley (rat) astrocytes after 4 days by cresylecth violet-staining method	10.1007/s00044-010-9356-8
C6	IC₅₀	9.3 μM Compound: BCNU	Cytotoxicity against rat C6 glioma cell line Cytotoxicity against rat C6 glioma cell line	[PMID: 16970409]
C6	EC₅₀	4.8 μM Compound: 1, BCNU, Carmustine	Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method Cytotoxicity against Rattus norvegicus (rat) C6 cells after 4 days by cresylecth violet-staining method	10.1007/s00044-010-9356-8
CCD 19Lu	IC₅₀	300 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of CCD-19Lu fibroblasts cell line using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of CCD-19Lu fibroblasts cell line using the MTT Cytotoxicity Assay	[PMID: 2391696]
CHO	IC₅₀	8.2 μM Compound: Carmustine	Dose required to inhibit cell growth was determined against CHO cell line Dose required to inhibit cell growth was determined against CHO cell line	[PMID: 11262080]
DOD-1	IC₅₀	37 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of DOD-1 breast cell line using the MTT Cytotoxicity Assay	[PMID: 2391696]
HL-60	IC₅₀	30.5 μM Compound: BCNU	Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) HL60 cells after 96 hr by MTT assay	10.1007/s00044-011-9778-y
HT-29	IC₅₀	17 μM Compound: Carmustine	Dose required to inhibit cell growth was determined against HT-29 cell line of human adenocarcinoma Dose required to inhibit cell growth was determined against HT-29 cell line of human adenocarcinoma	[PMID: 11262080]
K562	IC₅₀	9 μM Compound: Carmustine	Dose required to inhibit cell growth was determined against K562 cell line of chronic myelogenous leukemia Dose required to inhibit cell growth was determined against K562 cell line of chronic myelogenous leukemia	[PMID: 11262080]
L1210	IC₅₀	4.5 μM Compound: Carmustine	Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia Dose required to inhibit cell growth was determined against L1210 cell line of murine lymphocytotic leukemia	[PMID: 11262080]
L1210	ED₅₀	4 μM Compound: BCNU	Compound was tested in vitro for cytotoxicity against L1210 leukemia cells in tumor bearing mice. Compound was tested in vitro for cytotoxicity against L1210 leukemia cells in tumor bearing mice.	[PMID: 2939245]
L1210	ED₅₀	4 μM Compound: BCNU	Cytotoxicity against mouse L1210 cells after 72 hrs by coulter counter analysis Cytotoxicity against mouse L1210 cells after 72 hrs by coulter counter analysis	[PMID: 563461]
L1210	ED₅₀	4 μM Compound: BCNU	In vitro inhibitory activity against murine leukemia L1210 cells In vitro inhibitory activity against murine leukemia L1210 cells	[PMID: 6256551]
L1210	ED₅₀	20 mg/kg Compound: Table III, R37C1	Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse assessed as increase of life span of host measured up to 45 days	[PMID: 836500]
LOX IMVI	IC₅₀	7 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of LOX melanoma cell line using the MTT Cytotoxicity Assay	[PMID: 2391696]
Malme-3M	IC₅₀	20 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of MALME-3M melanoma cell line using the MTT Cytotoxicity Assay	[PMID: 2391696]
MCF7	IC₅₀	4.5 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7 breast cell line using the MTT Cytotoxicity Assay	[PMID: 2391696]
MDA-MB-231	IC₅₀	7.4 μM Compound: Carmustine	Dose required to inhibit cell growth was determined against MDA-MB-231 cell line of human non-hormone dependent breast carcinoma Dose required to inhibit cell growth was determined against MDA-MB-231 cell line of human non-hormone dependent breast carcinoma	[PMID: 11262080]
NCH89	IC₅₀	615 μM Compound: Carmustine	Antiproliferative activity against human NCH-89 cells assessed as BrdU incorporation after 48 hrs Antiproliferative activity against human NCH-89 cells assessed as BrdU incorporation after 48 hrs	[PMID: 20329733]
NCI/ADR-RES	IC₅₀	20 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of MCF-7ADR breast cell line using the MTT Cytotoxicity Assay	[PMID: 2391696]
NCI-H125	IC₅₀	9 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of H125 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay	[PMID: 2391696]
NCI-H23	IC₅₀	5 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of H23 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay	[PMID: 2391696]
NCI-H322M	IC₅₀	60 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of H322M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of H322M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay	[PMID: 2391696]
NCI-H358	IC₅₀	98 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of H358M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of H358M cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay	[PMID: 2391696]
NCI-H460	IC₅₀	80 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of H460 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of H460 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay	[PMID: 2391696]
NCI-H520	IC₅₀	20 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of H522 cell line of lung using the Microculture Tetrazolium (MTT) Cytotoxicity Assay	[PMID: 2391696]
OVCAR-3	IC₅₀	15 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-3 ovarian cell line using the MTT Cytotoxicity Assay	[PMID: 2391696]
OVCAR-4	IC₅₀	18 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of OVCAR-4 ovarian cell line using the MTT Cytotoxicity Assay	[PMID: 2391696]
P388	IC₅₀	5.9 μM Compound: Carmustine	Dose required to inhibit cell growth was determined against P388D1 cell line of murine lymphocytotic leukemia Dose required to inhibit cell growth was determined against P388D1 cell line of murine lymphocytotic leukemia	[PMID: 11262080]
P388	ED₅₀	13.3 μM Compound: BCNU	Mean value for the exposure for P388 to the drug for a period of 60 min Mean value for the exposure for P388 to the drug for a period of 60 min	[PMID: 6226795]
P388	ED₅₀	6.3 μM Compound: BCNU	Mean value for the exposure for P388 to the drug for a period of 40 min at pH 7.4 and 37 degree Mean value for the exposure for P388 to the drug for a period of 40 min at pH 7.4 and 37 degree	[PMID: 6226795]
SF-126	IC₅₀	20 μM Compound: BCNU	Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay	[PMID: 27041398]
SF-126	IC₅₀	25 μM Compound: BCNU	Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG	[PMID: 27041398]
SF-126	IC₅₀	55 μM Compound: BCNU	Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay	[PMID: 28197307]
SF-126	IC₅₀	85 μM Compound: BCNU	Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 28197307]
Sf21	IC₅₀	>1000 μM Compound: Carmustine	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	>1000 μM Compound: Carmustine	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
SK-MEL-5	IC₅₀	27 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of SK-MEL-5 melanoma cell line using the MTT Cytotoxicity Assay	[PMID: 2391696]
TE-671	IC₅₀	25 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of TE-671 cell line of central nervous system (CNS)using the MTT Cytotoxicity Assay	[PMID: 2391696]
U-251	IC₅₀	15 μM Compound: BCNU	Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay Evaluated for the inhibitory concentration required to cause growth inhibition of U251 cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay	[PMID: 2391696]
U-87MG ATCC	IC₅₀	1.42 μM Compound: BCNU	In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr In vitro inhibitory concentration against growth of U87MG glioblastoma cell line in clonogenic survival assay after 24 hr	[PMID: 15603970]
U-87MG ATCC	IC₅₀	3.9 μg/mL Compound: Carmustine	Antiproliferative activity against human U87 cells assessed as reduction in cell viability by MTT assay Antiproliferative activity against human U87 cells assessed as reduction in cell viability by MTT assay	[PMID: 33276991]
U-87MG ATCC	IC₅₀	3.9 μM Compound: Carmustine	Antiproliferative activity against human U87 cells Antiproliferative activity against human U87 cells	[PMID: 33421712]
U-87MG ATCC	IC₅₀	3.9 μg/mL Compound: BCNU	Cytotoxicity against Homo sapiens (human) U87 cells by MTT assay Cytotoxicity against Homo sapiens (human) U87 cells by MTT assay	10.1007/s00044-012-0249-x
U-937	IC₅₀	12.3 μM Compound: BCNU	Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay Cytotoxicity against Homo sapiens (human) U937 cells after 96 hr by MTT assay	10.1007/s00044-011-9778-y

In Vitro

Carmustine is an antitumor chemotherapeutic agent. Carmustine (8, 80, and 800 μM) decreases N-acetyltransferase (NAT) activities for 2-aminofluorene (AF) and p-aminobenzoic acid (PABA) in rat glial tumor cytosol and intact cells. In rat glial tumor cells, the DNA-AF adduct increases, and carmustine decreases the formation of DNA-AF adduct^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Carmustine (BCNU; 25 mg/kg, i.p.) causes higher levels of the rhe ratio of liver weight to body weight and plasma conjugated bilirubin, and lower biliary flow, oxidised glutation levels (GSSG) and reduced glutation (GSH)/GSSG values compared with control rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 154-93-8
Appearance <30°C Solid,>30°C Liquid
Masse moléculaire 214.05
Formule C₅H₉Cl₂N₃O₂
Color White to yellow
SMILES

O=C(NCCCl)N(CCCl)N=O
Synonyms

BCNU
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

-20°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (11)

All Flow CytometryCell Proliferation/Viability AssayIn Vivo Efficacy StudyCell Imaging/Staining

Sort by:

Journal Impact Factor

Nat Cell Biol

Full-length GSDME mediates pyroptosis independent from cleavage. [Abstract]

2024 Sep;26(9):1545-1557. PMID: 38997456

Carmustine purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Sep;26(9):1545-1557. [Abstract]

C57BL/6J mice bearing GSDME-overexpressing murine melanoma B16 cell-derived xenografts were treated intraperitoneally with Carmustine (20 mg/kg) and RSL3 (10 mg/kg) daily for 1 week. Xenograft tumours and their corresponding tumour weights are indicated (n = 7). PBS was used as a control. The results demonstrated that the combination of Carmustine and RSL3 effectively suppressed tumor growth.

Carmustine purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Sep;26(9):1545-1557. [Abstract]

RSL3 (100 nM) combined with different reagents, including MMS (methyl methanesulfonate, 1 mM), MNNG (N-methyl-N’-nitro-N’-nitrosoguanidine, 0.3 mM) and Carmustine (0.25 mM)), were used to treated cells, the pyroptotic morphologies were observed. RSL3 combined with lower dose of UVC irradiation (50 mJ cm^-2) was used as a positive control.
Biomaterials

A Sub-6 nm MnFe2O4-dichloroacetic acid nanocomposite modulates tumor metabolism and catabolism for reversing tumor immunosuppressive microenvironment and boosting immunotherapy. [Abstract]

2022 May;284:121533. PMID: 35462304

Carmustine purchased from MedChemExpress. Usage Cited in: Biomaterials. 2022 May;284:121533. [Abstract]

Quantitative analysis of intracellular GSH using flow cytometry. Carmustine was used as positive control. ROS and GSH analysis were performed with 4T1 cells upon treatment for 6 h.
Adv Healthc Mater

Forming a Precise and Reproducible Hypoxic Tumor Microenvironment in Glioblastoma by High Cell Density Bioprinting. [Abstract]

2026 Jun 10:e71322. PMID: 42272125
Acta Pharmacol Sin

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]

2021 Jan;42(1):108-114. PMID: 32398685
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
J Drug Deliv Sci Technol

9 September 2022, 103770.

Carmustine purchased from MedChemExpress. Usage Cited in: J Drug Deliv Sci Technol. 9 September 2022, 103770.

Dose response curves of free drugs and drug-loaded nanoparticles. In vitro cell viability assays of U251 cells after 48 h of incubation with Carmustine (BCNU, 62.5-500 μM), BCNU-loaded Fe3O4@MIL-88B–NH2 nanocomposites.
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Cancer Sci

Resveratrol as a Novel YAP Inhibitor Targeting Glioblastoma Progression and Sensitizing to Chemotherapy. [Abstract]

2026 Mar;117(3):695-710. PMID: 41518046

Carmustine purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2026 Mar;117(3):695-710. [Abstract]

RV increases the sensitivity of GBM cells to chemotherapeutic agents. Graphs show GBM cell viability after 48 h treatment with 50 μM RV combined with 50 μM TMZ or 50 μM Carmustine (BCNU), compared to DMSO and untreated controls (Ctrl).
J Mol Med (Berl)

Combination of PARP inhibitor and temozolomide to suppress chordoma progression. [Abstract]

2019 Aug;97(8):1183-1193. PMID: 31201471
Mol Imaging Biol

Evaluation of Glycolytic Response to Multiple Classes of Anti-glioblastoma Drugs by Noninvasive Measurement of Pyruvate Kinase M2 Using [18F]DASA-23. [Abstract]

2020 Feb;22(1):124-133. PMID: 30989436
SSRN

2026 Jan 26.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (467.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 100 mg/mL (467.18 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.6718 mL

23.3590 mL

46.7181 mL

5 mM

0.9344 mL

4.6718 mL

9.3436 mL

10 mM

0.4672 mL

2.3359 mL

4.6718 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (9.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (9.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (9.72 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (467.18 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protocole

Kinase Assay^[1]

The determination of Acetyl-CoAdependent N-acetylation of 2-aminofluorene (AF) and p-aminobenzoic acid (PABA) are performed. Incubation mixtures in the assay system consists of a total volume of 90 μL: glial tumor cells cytosols, diluted as required, in 50 μL of lysis buffer (20 mM Tris/HCl, pH 7.5, 1 mM DTT and 1 mM EDTA), 20 μL of an Acetyl-CoA recycling mixture of 50 mM Tris-HCl (pH7.5), 0.2 mM EDTA, 2 mM DTT, 15 mM acetylcamitine, 2U/mL carnitine acetyltransferase, and AF or PABA at specific concentrations. The reactions are started by addition of 20 μL of Acetyl-CoA. The control reactions have 20 μL distilled water in place of Acetyl-CoA. For the single point activity measurements, the final concentration of AF or PABA is 0.1 mM and AcCoA is 0.5 mM. The reaction mixtures with or without specific concentrations of Carmustine and lomustine are incubated at 37°C for 10 min and stopped with 50 μL of 20% trichloroacetic acid for the PABA reactions, and 100 μL of acetonitrile for the AF reactions. All of the reactions (experiments and controls) are run in triplicate^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Rats^[2]
Individual rats are weighted prior to enter the study; their weights are recorded, and they are randomLy assigned to four groups. Group I (saline group); This group consists of 12 rats. These rats are injected with 2 mL/kg of saline intraperitoneally (IP) 48 h before the study, being included by the study 48 h later. Group II (corn oil group) consists of 15 rats. These rats are injected with 2 mL/kg of corn oil (vehicle) IP 48 h before the study. Group III (Carmustine group) consists of 16 rats. These rats are injected with 1 mL per day of saline IP, administered at the same hour of the day as a single-dose for 3 days. Twelve hours after the first dose of saline, corn oil 2 mL/kg + Carmustine 25 mg/kg IP are injected, and the rats are included in the study 48 h after the administration of corn oil + Carmustine. Group IV (trimetazidine group) consists of 12 rats. These rats are injected with 2.5 mg/kg per day of trimetazidine (TMZ) IP, administered at the same hour of the day as a single-dose for 3 days. 12 h after the first dose of TMZ, corn oil 2 mL/kg + Carmustine 25 mg/kg IP are injected, and the rats are included in the study 48 h after the administration of corn oil + Carmustine^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (276 KB)
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Hung CF. Effects of carmustine and lomustine on arylamine N-acetyltransferase activity and 2-aminofluorene-DNA adducts in rat glial tumor cells. Neurochem Res. 2000 Jun;25(6):845-51. [Content Brief]

[2]. Demir A, et al. The effect of trimetazidine on intrahepatic cholestasis caused by carmustine in rats. Hepatol Res. 2001 May 1;20(1):133-143. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	4.6718 mL	23.3590 mL	46.7181 mL	116.7951 mL
	5 mM	0.9344 mL	4.6718 mL	9.3436 mL	23.3590 mL
	10 mM	0.4672 mL	2.3359 mL	4.6718 mL	11.6795 mL
	15 mM	0.3115 mL	1.5573 mL	3.1145 mL	7.7863 mL
	20 mM	0.2336 mL	1.1680 mL	2.3359 mL	5.8398 mL
	25 mM	0.1869 mL	0.9344 mL	1.8687 mL	4.6718 mL
	30 mM	0.1557 mL	0.7786 mL	1.5573 mL	3.8932 mL
	40 mM	0.1168 mL	0.5840 mL	1.1680 mL	2.9199 mL
	50 mM	0.0934 mL	0.4672 mL	0.9344 mL	2.3359 mL
	60 mM	0.0779 mL	0.3893 mL	0.7786 mL	1.9466 mL
	80 mM	0.0584 mL	0.2920 mL	0.5840 mL	1.4599 mL
	100 mM	0.0467 mL	0.2336 mL	0.4672 mL	1.1680 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Carmustine

11 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Carmustine

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Food-Sourced Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Carmustine

Activité biologique

Chemical Information

Publications (11)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Carmustine

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Food-Sourced Compound Library

Tumorigenesis-Related Compound Library

Rare Diseases Drug Library

Chemotherapy Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Carmustine

Activité biologique

Chemical Information

Publications (11)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Carmustine Related Classifications

HY-13585 Related Classifications